close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.585 +0.065 (+1.85%)
Delayed Quote Updated: 11:39 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Wave Life Sciences (WVE) Q3 2026 Earnings Call Transcript ↗
RNA medicine company advances obesity and lung disease programs with $431M cash runway. 
Via The Motley Fool
Topics Earnings
News headline image
WAVE Life Sciences Q3 Earnings Call Highlights ↗
WAVE Life Sciences (NASDAQ:WVE) reported higher third-quarter revenue and a wider net loss as it increased investment in clinical programs spanning obesity, alpha-1 antitrypsin deficiency and liver... 
Via MarketBeat
Topics Earnings
News headline image
WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path ↗
WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno emphasizing the... 
Via MarketBeat
Wave Life Sciences (NASDAQ:WVE) Plunges After Q2 Revenue Miss ↗
Via Chartmill
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates ↗
Via Chartmill
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Mixed Q4 2025 Results, Highlights Extended Cash Runway to 2028 ↗
Via Chartmill
The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗
Via Stocktwits
News headline image
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials. 
Via The Motley Fool
Topics Earnings
News headline image
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials. 
Via The Motley Fool
Topics Earnings
News headline image
WAVE Life Sciences Q2 Earnings Call Highlights ↗
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones... 
Via MarketBeat
Topics Earnings
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wave (WVE) Q1 2026 Earnings Call Transcript ↗
Wave (WVE) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q2 2025 Earnings Call Transcript ↗
Wave (WVE) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q1 2025 Earnings Call Transcript ↗
Wave (WVE) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Is This Weight Loss Drug Stock a Buy on the Dip? ↗
This company's anti-obesity candidate might succeed where others are failing. 
Via The Motley Fool
News headline image
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity. 
Via The Motley Fool
Topics Stocks
Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
Via Chartmill
Here are the top movers in Thursday's session. ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
Via MarketMinute
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Wave Life Sciences (WVE) Earnings Call Transcript ↗
Wave Life Sciences (WVE) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company. ↗
This biotech innovator in genetic medicines reported significant insider selling, as disclosed in recent SEC filings. 
Via The Motley Fool
Topics Regulatory Compliance
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Golden Cross Alert: 3 Stocks With Major Upside Potential ↗
Via MarketBeat
News headline image
Why Wave Life Sciences Stock Crushed it Again Today ↗
There's nothing like a nearly 150% price gain to garner the attention of investors and analysts. 
Via The Motley Fool
News headline image
Which stocks have an unusual volume on Tuesday? ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Why Wave Life Sciences Stock Vaulted 146% Higher on Monday ↗
We have an emerging new entrant in the increasingly crowded weight loss drug space. 
Via The Motley Fool
News headline image
Which stocks are most active on Monday? ↗
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.